Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has been given an average recommendation of "Buy" by the eight ratings firms that are covering the company, Marketbeat reports. Eight analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $6.63.

Several research firms recently weighed in on TSHA. Chardan Capital reiterated a "buy" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Needham & Company LLC restated a "buy" rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TSHA. Charles Schwab Investment Management Inc. lifted its position in Taysha Gene Therapies by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock worth $820,000 after buying an additional 11,390 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Taysha Gene Therapies by 23.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company's stock valued at $7,163,000 after buying an additional 682,273 shares during the period. Wellington Management Group LLP bought a new stake in shares of Taysha Gene Therapies in the 3rd quarter valued at $931,000. Barclays PLC raised its stake in Taysha Gene Therapies by 356.0% during the 3rd quarter. Barclays PLC now owns 247,280 shares of the company's stock worth $513,000 after buying an additional 193,046 shares during the period. Finally, State Street Corp lifted its holdings in Taysha Gene Therapies by 4.5% during the third quarter. State Street Corp now owns 3,469,068 shares of the company's stock worth $6,973,000 after acquiring an additional 150,647 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Taysha Gene Therapies Stock Performance

Taysha Gene Therapies stock traded down $0.05 on Friday, reaching $1.16. 384,865 shares of the stock were exchanged, compared to its average volume of 2,689,745. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The firm has a fifty day moving average price of $1.60 and a two-hundred day moving average price of $1.85. The stock has a market cap of $236.78 million, a PE ratio of 1.83 and a beta of 0.96. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The company had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. Sell-side analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.